[go: up one dir, main page]

EA201990032A1 - Способы и композиции для терапии посредством потенциирования стволовых клеток - Google Patents

Способы и композиции для терапии посредством потенциирования стволовых клеток

Info

Publication number
EA201990032A1
EA201990032A1 EA201990032A EA201990032A EA201990032A1 EA 201990032 A1 EA201990032 A1 EA 201990032A1 EA 201990032 A EA201990032 A EA 201990032A EA 201990032 A EA201990032 A EA 201990032A EA 201990032 A1 EA201990032 A1 EA 201990032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
therapy
potentiating
methods
stem cells
Prior art date
Application number
EA201990032A
Other languages
English (en)
Inventor
Уильям Клейдон
Original Assignee
ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи filed Critical ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи
Publication of EA201990032A1 publication Critical patent/EA201990032A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Настоящее изобретение относится к каннабиноидным композициям, используемым в сочетании с лечением стволовыми клетками. Указанные композиции могут быть заключены в капсулы (например, в микрокапсулы). В частности, указанные композиции можно вводить индивидууму перорально или местно.
EA201990032A 2016-06-15 2017-06-15 Способы и композиции для терапии посредством потенциирования стволовых клеток EA201990032A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662350708P 2016-06-15 2016-06-15
PCT/US2017/037787 WO2017218846A1 (en) 2016-06-15 2017-06-15 Methods and compositions for potentiating stem cell therapies

Publications (1)

Publication Number Publication Date
EA201990032A1 true EA201990032A1 (ru) 2019-06-28

Family

ID=60663800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990032A EA201990032A1 (ru) 2016-06-15 2017-06-15 Способы и композиции для терапии посредством потенциирования стволовых клеток

Country Status (10)

Country Link
US (2) US20190247358A1 (ru)
EP (1) EP3472307A4 (ru)
JP (2) JP2019518760A (ru)
CN (1) CN109642215A (ru)
AU (1) AU2017286656A1 (ru)
BR (1) BR112018076283A2 (ru)
CA (1) CA3027885A1 (ru)
EA (1) EA201990032A1 (ru)
IL (1) IL263696A (ru)
WO (1) WO2017218846A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3606341A4 (en) 2017-04-04 2021-04-21 The Board of Trustees of the Leland Stanford Junior University PREPARATION, EXPANSION AND USES OF ADULT PLURIPOTENT STEM CELLS
SG11202102737XA (en) * 2018-09-21 2021-04-29 Apstem Therapeutics Inc Human pluripotent adult stem cells
GB2615034A (en) 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
EP3941458A4 (en) * 2019-03-21 2022-05-25 Alvit LCS Pharma Ltd. FIXED-DOSE COMBINATION OF CANNABINOIDS AND MEDICAL MUSHROOMS FOR THE PREVENTION AND TREATMENT OF CANCER, INFLAMMATORY OR IMMUNE-MEDIATED INFLAMMATORY DISEASES
WO2020255133A1 (en) * 2019-06-18 2020-12-24 The Cures Ltd. Novel therapeutic preparations comprising scutellaria barbata
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN112626012A (zh) * 2019-09-20 2021-04-09 深圳市未来细胞生命科技有限公司 一种促进干细胞生长的培养液及其制作方法
CN113116870A (zh) * 2019-12-31 2021-07-16 四川大学 大麻二酚在制备促进口腔黏膜愈合的药物中的应用
WO2021188865A1 (en) * 2020-03-19 2021-09-23 New York Medical College Cannabinoid medical carrier
CN113559125A (zh) * 2020-04-26 2021-10-29 苏州大学 一种治疗糖尿病的干细胞药物
WO2022086276A1 (ko) * 2020-10-22 2022-04-28 가톨릭대학교 산학협력단 특정 유전자의 발현이 증가 또는 감소된 줄기세포를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물
US11844361B2 (en) 2021-04-08 2023-12-19 Wiparo Biomed Limited Stem cell boosting chocolate composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
NZ566132A (en) * 2003-02-13 2009-09-25 Anthrogenesis Corp Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20100087436A1 (en) * 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
AR095962A1 (es) * 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
WO2014178048A1 (en) * 2013-05-02 2014-11-06 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
AU2014347807A1 (en) * 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CN107205981A (zh) * 2014-12-12 2017-09-26 奥海能量公益公司 微胶囊化大麻素组合物
US10028919B2 (en) * 2015-03-10 2018-07-24 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms

Also Published As

Publication number Publication date
US20240238239A1 (en) 2024-07-18
US20190247358A1 (en) 2019-08-15
BR112018076283A2 (pt) 2019-03-26
JP2019518760A (ja) 2019-07-04
WO2017218846A1 (en) 2017-12-21
CN109642215A (zh) 2019-04-16
AU2017286656A1 (en) 2019-01-17
IL263696A (en) 2019-01-31
EP3472307A4 (en) 2020-03-25
EP3472307A1 (en) 2019-04-24
JP2022159419A (ja) 2022-10-17
CA3027885A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
EA201990032A1 (ru) Способы и композиции для терапии посредством потенциирования стволовых клеток
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2016005689A (es) Celulas no t efectoras y madre/progenitoras hematopoyeticas modificadas y usos de estas.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201990043A1 (ru) Антибактериальные соединения
EA201890204A1 (ru) Антибактериальные соединения
MY196173A (en) Cot Modulators And Methods Of Use Thereof
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
CR20160170A (es) Moduladores del factor del complemento b
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2021015825A (es) Formulaciones de anticuerpos estables acuosas.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
EA202090270A1 (ru) Новые замещенные производные ксантина
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба